The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases

EGFR 돌연변이가 있는 폐의 육종양 암종에서의 Gefitinib을 사용하여 치료한 2예

  • Kim, Ji-Yeon (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Lim, Yoojoo (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Lee, Eunyoung (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Kim, Mi So (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Lee, Dae-Won (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
  • 김지연 (서울대학교 의과대학 서울대학교병원 내과, 암연구소) ;
  • 임유주 (서울대학교 의과대학 서울대학교병원 내과, 암연구소) ;
  • 이은영 (서울대학교 의과대학 서울대학교병원 내과, 암연구소) ;
  • 김미소 (서울대학교 의과대학 서울대학교병원 내과, 암연구소) ;
  • 이대원 (서울대학교 의과대학 서울대학교병원 내과, 암연구소) ;
  • 김태민 (서울대학교 의과대학 서울대학교병원 내과, 암연구소) ;
  • 이세훈 (서울대학교 의과대학 서울대학교병원 내과, 암연구소)
  • Received : 2012.07.24
  • Accepted : 2012.08.13
  • Published : 2013.03.01
⟨ Previous Next ⟩

Abstract

Sarcomatoid carcinoma of the lung is defined as a group of poorly differentiated non-small cell carcinomas that contain a component of sarcoma or a sarcoma-like element. Most sarcomatoid carcinomas are known to have a poor prognosis. We describe a 45-year-old female never smoker and 49-year-old female never smoker with sarcomatoid carcinomas of the lung that expressed a specific EGFR mutation: microdeletion of exon 19. Their cancers progressed rapidly, despite appropriate conventional chemotherapy. After they took the EGFR-targeted agent gefitinib, there was a dramatic reduction in tumor size. Sarcomatoid carcinoma of the lung is a rare cancer whose pathogenesis is not well understood. According to these cases, the EGFR mutation could be a driver mutation and the potential therapeutic target of EGFR-targeted agents for sarcomatoid carcinoma in lung cancer patients, especially never smokers.

저자들은 EGFR 돌연변이가 있는 폐의 육종양 암종에서 EGFR 표적치료제인 gefitinib을 사용하여 치료한 2예를 경험하였고, 부분관해(partial response) 이상의 반응을 나타내었다. 이에 증례고찰과 함께 보고하는 바이다.

Keywords

References

  1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068. https://doi.org/10.1183/09031936.01.00275301
  2. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010;18:103-120. https://doi.org/10.1177/1066896908330049
  3. Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol 2009;39:267-270. https://doi.org/10.1093/jjco/hyn155
  4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388. https://doi.org/10.1056/NEJMoa0909530
  5. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. https://doi.org/10.1126/science.1099314
  6. Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010;5:460-465. https://doi.org/10.1097/JTO.0b013e3181ce3e3c
  7. Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009;125:2479-2482. https://doi.org/10.1002/ijc.24610
  8. Lee S, Kim Y, Sun JM, et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011;137:1203-1211. https://doi.org/10.1007/s00432-011-0986-0
  9. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. https://doi.org/10.1371/journal.pmed.0020073
  10. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.

Cited by

  1. EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features vol.19, pp.1, 2013, https://doi.org/10.5114/wo.2014.43491